Literature DB >> 144508

A double-blind trial of high versus conventional dosages of gold salts for rheumatoid arthritis.

D E Furst, S Levine, R Srinivasan, A L Metzger, R Bangert, H E Paulus.   

Abstract

In a double-blind study, patients were randomly selected for treatment using conventional doses (CD; 50 mg) or high doses (HD; 150 mg) of sodium aurothiomalate given weekly by injection. Twenty-three patients were assigned to the CD group and 24 to the HD group. Neither efficacy nor toxicity correlated with serum gold concentrations. Conventional doses were as efficacious as high doses with respect to both rapidity and degree of response. However, side effects were much more frequent and severe in the HD group. Thus there is no reason to recommend a 150 mg weekly dosage regimen.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 144508     DOI: 10.1002/art.1780200805

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  14 in total

1.  Binding of sodium aurothiomalate to human serum albumin in vitro at physiological conditions.

Authors:  S M Pedersen
Journal:  Ann Rheum Dis       Date:  1986-09       Impact factor: 19.103

Review 2.  Drug toxicity.

Authors:  H A Bird
Journal:  Ann Rheum Dis       Date:  1990-05       Impact factor: 19.103

Review 3.  Clinical pharmacokinetics of oral and injectable gold compounds.

Authors:  K L Blocka; H E Paulus; D E Furst
Journal:  Clin Pharmacokinet       Date:  1986 Mar-Apr       Impact factor: 6.447

4.  Aurothioglucose overdosage in five patients with rheumatoid arthritis.

Authors:  I Rubinstein; P Langevitz; M Pras
Journal:  Clin Rheumatol       Date:  1987-12       Impact factor: 2.980

Review 5.  Antirheumatic drugs: clinical pharmacology and therapeutic use.

Authors:  G L Craig; W W Buchanan
Journal:  Drugs       Date:  1980-12       Impact factor: 9.546

6.  Quantitation and characterization of soluble immune complexes precipitated from sera by polyethylene glycol (PEG).

Authors:  D Chia; E V Barnett; J Yamagata; D Knutson; C Restivo; D Furst
Journal:  Clin Exp Immunol       Date:  1979-09       Impact factor: 4.330

7.  Comparative pharmacokinetics of triethylphosphine gold (auranofin) and gold sodium thiomalate (GST).

Authors:  D E Furst; S H Dromgoole
Journal:  Clin Rheumatol       Date:  1984-03       Impact factor: 2.980

Review 8.  Remission-inducing drugs in rheumatoid arthritis.

Authors:  T P Anastassiades
Journal:  Can Med Assoc J       Date:  1980-02-23       Impact factor: 8.262

9.  Measurement of clinical change in progressive systemic sclerosis: a 1 year double-blind placebo-controlled trial of N-acetylcysteine.

Authors:  D E Furst; P J Clements; R Harris; M Ross; J Levy; H E Paulus
Journal:  Ann Rheum Dis       Date:  1979-08       Impact factor: 19.103

10.  Additive two DMARD therapy of the patients with rheumatoid arthritis.

Authors:  M Yasuda; S Nonaka; T Wada; M Yamamoto; S Shiokawa; Y Suenaga; M Nobunaga
Journal:  Clin Rheumatol       Date:  1994-09       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.